[{"orgOrder":0,"company":"Walden Biosciences","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Launches to Transform the Treatment of Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Announces Research Collaboration with University of Michigan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Expands Research Collaboration with the University of Michigan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Primula Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Walden Biosciences
The collaboration aims to lever a large body of genetic data on patients living with chronic kidney disease, to further support the clinical advancement of Walden’s WAL0921, an anti-suPAR antibody.
WAL0921 is the first in class, proprietary, humanized monoclonal antibody that binds soluble urokinase plasminogen activator receptor, inhibiting the pro-inflammatory action that causes podocyte dysfunction and renal disease.
Under the collaboration, Walden and U-M will analyze the effect in plasma of reducing suPAR levels seen in Walden’s single ascending dose study of WAL0921, first-in-class, proprietary, humanized monoclonal antibody that binds suPAR, in healthy subjects.
WAL0921 is the first in class, proprietary, humanized monoclonal antibody that binds soluble urokinase plasminogen activator receptor (suPAR), inhibiting the pro-inflammatory action that causes podocyte dysfunction and renal disease.
U-M will collaborate with Walden Biosciences in connection with Dr. Hayek’s ongoing research in the area of suPAR and Walden will provide materials, data analysis, and may perform experiments to support the work, including the role of polymorphisms in the PLAUR gene.
Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function.